ESR1 and breast neoplasm: Importantly, the presence of these receptors continues to serve as some of the most effective therapeutic targets in all of oncology, particularly for patients harboring breast tumors belonging to the luminal A (ER-α- and PR-positive), luminal B (ER-α and HER2-positive), and HER2 subtypes [6].